Fig. 6: Regorafenib inhibits PLEKHA1-TACC2 activity and tumor progression. | Cell Death & Differentiation

Fig. 6: Regorafenib inhibits PLEKHA1-TACC2 activity and tumor progression.

From: The PLEKHA1-TACC2 fusion gene drives tumorigenesis via vascular mimicry formation in esophageal squamous-cell carcinoma

Fig. 6

A The expression of total EphA2, p-EphA2 (S897), total AKT, and p-AKT (S473) in KYSE30 and KYSE150 cells stably expressing Flag-tagged Pe4Te20 treated with indicated concentration of regorafenib for 48 h was determined by immunoblotting analyses. B The VM ability of KYSE30 and KYSE150 cells stably expressing Flag-tagged Pe4Te20, Pe11Te17, Pe10Te23, Pe5Te17, Pe2Te23, without or with regorafenib (4 μM) treatment was performed using an in vitro tube formation assay. C The images of the tumors from the indicated transgenic mice following 4-NQO treatment first then 28 days of regorafenib or vehicle treatment (n = 8, each subgroup). D The number of tumors from the indicated transgenic mice following 4-NQO treatment first then 28 days of regorafenib or vehicle treatment. One-way ANOVA was used for analysis. E The size of tumors from the indicated transgenic mice following 4-NQO treatment first then 28 days of regorafenib or vehicle treatment. The P values were calculated using contingency table analysis. F Tumor differentiation stages by histopathological analysis of the tongue and esophagus from the indicated transgenic mice following 4-NQO treatment first then 28 days of regorafenib or vehicle treatment. G Representative images of hematoxylin-eosin staining of tongue and esophagus obtained from the indicated transgenic mice following 4-NQO treatment first then 28 days of regorafenib or vehicle treatment. Scale bars were indicated in the images. H The expression of total EphA2 and p-EphA2 (S897) in tongue (top) and esophagus (bottom) obtained from the indicated transgenic mice following 4-NQO treatment first then 28 days of regorafenib or vehicle treatment. Scale bars were indicated in the images. I Representative images of CD31/PAS/Ter119 staining of tongue and esophagus obtained from the indicated transgenic mice following 4-NQO treatment first then 28 days of regorafenib or vehicle treatment. Red arrows: the tubule-like VM channels. Blue arrows: the blood vessels lined by CD31-positive endothelial cells. Scale bars were indicated in the images. *P < 0.05, **P < 0.01, ns indicates no signifance.

Back to article page